[go: up one dir, main page]

HUE054444T2 - Prolinnal lezárt kapcsos peptidek és felhasználásuk - Google Patents

Prolinnal lezárt kapcsos peptidek és felhasználásuk

Info

Publication number
HUE054444T2
HUE054444T2 HUE13777368A HUE13777368A HUE054444T2 HU E054444 T2 HUE054444 T2 HU E054444T2 HU E13777368 A HUE13777368 A HU E13777368A HU E13777368 A HUE13777368 A HU E13777368A HU E054444 T2 HUE054444 T2 HU E054444T2
Authority
HU
Hungary
Prior art keywords
capped
proline
linked peptides
peptides
linked
Prior art date
Application number
HUE13777368A
Other languages
English (en)
Inventor
Gregory Verdine
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of HUE054444T2 publication Critical patent/HUE054444T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
HUE13777368A 2012-09-26 2013-09-26 Prolinnal lezárt kapcsos peptidek és felhasználásuk HUE054444T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705950P 2012-09-26 2012-09-26
US201361789157P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE054444T2 true HUE054444T2 (hu) 2021-09-28

Family

ID=49382577

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13777368A HUE054444T2 (hu) 2012-09-26 2013-09-26 Prolinnal lezárt kapcsos peptidek és felhasználásuk

Country Status (18)

Country Link
US (4) US9617309B2 (hu)
EP (2) EP2920197B1 (hu)
JP (3) JP6506166B2 (hu)
CA (2) CA2925035C (hu)
CY (1) CY1125259T1 (hu)
DK (1) DK2920197T3 (hu)
ES (1) ES2874525T3 (hu)
HK (1) HK1213269A1 (hu)
HR (1) HRP20210707T1 (hu)
HU (1) HUE054444T2 (hu)
IL (4) IL237967B (hu)
LT (1) LT2920197T (hu)
PL (1) PL2920197T3 (hu)
PT (1) PT2920197T (hu)
RS (1) RS61957B1 (hu)
SI (1) SI2920197T1 (hu)
SM (1) SMT202100337T1 (hu)
WO (1) WO2014052647A2 (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
EP2376100B1 (en) 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2012532929A (ja) 2009-07-13 2012-12-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二機能性のステープリングされたポリペプチドおよびそれらの使用
WO2011038049A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2012021874A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with thioether linkers
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
US9617309B2 (en) * 2012-09-26 2017-04-11 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
MX2015005244A (es) 2012-11-01 2015-07-14 Aileron Therapeutics Inc Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos.
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
KR102637496B1 (ko) 2013-03-13 2024-02-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
AU2014278005B2 (en) 2013-06-14 2018-11-22 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
CN106573032B (zh) 2014-05-21 2022-03-18 哈佛大学的校长及成员们 Ras抑制肽和其用途
CN112245565A (zh) 2014-09-24 2021-01-22 艾瑞朗医疗公司 拟肽大环化合物及其用途
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
KR101972012B1 (ko) * 2014-11-28 2019-04-24 서울대학교산학협력단 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
TW201904941A (zh) * 2017-06-29 2019-02-01 大陸商廣州南沙龍沙有限公司 製備α-甲基-L-脯氨酸的方法
EP3678683A4 (en) 2017-09-07 2021-07-14 Fog Pharmaceuticals, Inc. AGENTS FOR MODULATING BETA-CATENIN FUNCTIONS AND RELATED METHODS
CN112119085B (zh) 2017-12-15 2025-04-01 丹娜-法伯癌症研究院有限公司 稳定肽-介导的靶向蛋白降解
ES2942631T3 (es) * 2017-12-15 2023-06-05 Stealth Biotherapeutics Inc Péptidos dirigidos a mitocondrias
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
WO2019157131A1 (en) 2018-02-07 2019-08-15 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2021016462A1 (en) 2019-07-24 2021-01-28 Stealth Biotherapeutics Corp The peptidomimetic compound (r)-2-amino-n-((s)-l-(((s)-5-amino-l-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-i-oxopropan-2-yl)-5-guanidinopentanamide in the treatment of neurodegenerative diseases
JP2023518413A (ja) * 2020-03-17 2023-05-01 フォグ ファーマシューティカルズ， インコーポレイテッド ヘリックス状ステープルペプチドおよびその使用
JP2023546561A (ja) 2020-10-14 2023-11-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ウイルスタンパク質および宿主タンパク質の分解のためのキメラコンジュゲートならびに使用方法
KR102520353B1 (ko) * 2021-01-13 2023-04-12 동국대학교 산학협력단 안정화된 폴리프롤린 ⅱ 나선구조를 갖는 펩타이드

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4730006A (en) 1986-01-27 1988-03-08 Merrell Dow Pharmaceuticals Inc. Derivatives of 2,6-diamino-3-haloheptanedioic acid
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
EP0360390A1 (en) * 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5120859A (en) 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
US5712418A (en) 1989-10-23 1998-01-27 Research Corporation Technologies, Inc. Synthesis and use of amino acid fluorides as peptide coupling reagents
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
EP1251135A3 (en) 1992-04-03 2004-01-02 California Institute Of Technology High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis thereof
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
US5770377A (en) 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
CA2209183A1 (en) 1994-12-29 1996-07-11 Joel L. Pomerantz Chimeric dna-binding proteins
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
JP3599346B2 (ja) 1995-05-04 2004-12-08 ザ スクリップス リサーチ インスティチュート 天然型化学連結反応によるタンパク質の合成
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6051554A (en) 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9702377D0 (en) * 1996-02-23 1997-03-26 Zeneca Ltd Peptide derivatives
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5663316A (en) 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
WO1998022122A1 (en) 1996-11-21 1998-05-28 Promega Corporation Alkyl peptide amides and applications
US6849428B1 (en) 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
JP2001524301A (ja) 1997-09-17 2001-12-04 ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ 新規治療用分子
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6875594B2 (en) 1997-11-13 2005-04-05 The Rockefeller University Methods of ligating expressed proteins
DE69913316T2 (de) 1998-01-07 2004-11-18 Debio Recherche Pharmaceutique S.A. Abbaubare, heterobifunktionelle polyethylenglykolacrylate, sowie damit herstellbare gele und konjugate
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
ID30262A (id) 1999-03-29 2001-11-15 Procter & Gamble Ligan reseptor melanokortin
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US7049290B2 (en) 2000-07-28 2006-05-23 Universität Zürich Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon
AU2001284942A1 (en) 2000-08-16 2002-02-25 Georgetown University Medical Center Small molecule inhibitors targeted at bcl-2
WO2002064790A2 (en) 2000-12-19 2002-08-22 The Johns Hopkins University Jfy1 protein induces rapid apoptosis
CA2471719A1 (en) 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
CA2482611A1 (en) 2002-04-22 2003-10-30 University Of Florida Functionalized nanoparticles and methods of use
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20040171809A1 (en) 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
ES2295692T3 (es) 2002-11-08 2008-04-16 F. Hoffmann-La Roche Ag Nuevos derivados de 4-alcoxioxazol sustituido como agonistas de ppar.
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
US7485630B2 (en) * 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use
US20070207947A1 (en) 2003-10-16 2007-09-06 Aplagen Gmbh Stabilized Peptides
ITMI20032102A1 (it) * 2003-10-30 2005-04-30 Univ Degli Studi Milano Composti peptidomimetici, procedimento stereoselettivo per la loro preparazione, loro uso come intermedi di sintesi di derivati biologicamente attivi.
BRPI0416258A (pt) 2003-11-05 2007-01-09 Dana Farber Cancer Inst Inc peptìdeos helicoidais alfa estabilizados e aplicações dos mesmos
GB0404731D0 (en) 2004-03-03 2004-04-07 Indp Administrative Inst Nims Method and products for the selective degradation of proteins
US8193310B2 (en) 2004-03-19 2012-06-05 The University Of Queensland Alpha helical mimics, their uses and methods for their production
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
US7501397B2 (en) 2004-06-04 2009-03-10 The Brigham And Women's Hospital, Inc. Helical peptidomimetics with enhanced activity
WO2006069001A2 (en) 2004-12-20 2006-06-29 Baylor College Of Medicine Structural requirements for stat3 binding and recruitment to phosphototyrosine ligands
BRPI0519148A2 (pt) * 2004-12-20 2008-12-30 Sigma Tau Ind Farmaceuti inibidores de homodimerizaÇço de myd88
WO2006103666A2 (en) 2005-03-28 2006-10-05 Yeda Research And Development Co. Ltd. Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
GB0511771D0 (en) * 2005-06-09 2005-07-20 Novartis Ag Organic compounds
US7745573B2 (en) 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
US7538190B2 (en) 2006-02-17 2009-05-26 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of two or more dicarba bridges in organic compounds
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
AU2007319193A1 (en) 2006-11-15 2008-05-22 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
CN105061577A (zh) 2006-12-14 2015-11-18 爱勒让治疗公司 双巯基大环化系统
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008104000A2 (en) 2007-02-23 2008-08-28 Aileron Therapeutics, Inc. Triazole macrocycle systems
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
WO2009042237A2 (en) 2007-09-26 2009-04-02 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
US20090326192A1 (en) 2008-04-08 2009-12-31 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
WO2010034034A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2737918A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2012509902A (ja) 2008-11-24 2012-04-26 エルロン・セラピューティクス・インコーポレイテッド 改善された特性を有するペプチド模倣大環状分子
EP3124494B1 (en) 2008-12-09 2019-06-19 Dana-Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
WO2010132869A2 (en) * 2009-05-15 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
DE102009032902A1 (de) * 2009-07-10 2011-01-13 Forschungsverbund Berlin E.V. Induktion von α-Helix-Konformationen in Proteinen und Peptiden
JP2012532929A (ja) 2009-07-13 2012-12-20 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二機能性のステープリングされたポリペプチドおよびそれらの使用
CA2777700A1 (en) 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles
US20110269244A1 (en) * 2009-12-30 2011-11-03 Petter Russell C Ligand-directed covalent modification of protein
US20130177979A1 (en) 2010-06-22 2013-07-11 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
US8957026B2 (en) 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012174409A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized variant maml peptides and uses thereof
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
US9617309B2 (en) * 2012-09-26 2017-04-11 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
US20150225471A1 (en) 2012-10-01 2015-08-13 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
KR102637496B1 (ko) 2013-03-13 2024-02-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스테이플드 및 스티치드 폴리펩티드 및 그의 용도

Also Published As

Publication number Publication date
US20240124525A1 (en) 2024-04-18
EP2920197A2 (en) 2015-09-23
HRP20210707T1 (hr) 2021-09-17
IL263145A (en) 2018-12-31
US9617309B2 (en) 2017-04-11
RS61957B1 (sr) 2021-07-30
WO2014052647A2 (en) 2014-04-03
US20150239937A1 (en) 2015-08-27
WO2014052647A3 (en) 2014-06-26
SI2920197T1 (sl) 2021-08-31
US20180009847A1 (en) 2018-01-11
SMT202100337T1 (it) 2021-07-12
CA2925035A1 (en) 2014-04-03
EP3872067A1 (en) 2021-09-01
CA2925035C (en) 2021-05-25
EP2920197B1 (en) 2021-03-17
ES2874525T3 (es) 2021-11-05
JP2016500658A (ja) 2016-01-14
DK2920197T3 (da) 2021-05-31
IL283139A (en) 2021-06-30
PT2920197T (pt) 2021-06-11
CY1125259T1 (el) 2023-03-24
IL274236B (en) 2021-05-31
JP6506166B2 (ja) 2019-04-24
IL237967B (en) 2018-12-31
JP2019142886A (ja) 2019-08-29
JP2022018119A (ja) 2022-01-26
JP7435991B2 (ja) 2024-02-21
JP7448966B2 (ja) 2024-03-13
LT2920197T (lt) 2021-06-25
IL274236A (en) 2020-06-30
US20220177522A1 (en) 2022-06-09
CA3113959A1 (en) 2014-04-03
HK1213269A1 (zh) 2016-06-30
PL2920197T3 (pl) 2021-09-13

Similar Documents

Publication Publication Date Title
HUS2200034I1 (hu) Glikokonjugációs eljárások és kompozíciók
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
HUE054444T2 (hu) Prolinnal lezárt kapcsos peptidek és felhasználásuk
HK1253343A1 (zh) 新穎縮肽及其用途
HUE040111T2 (hu) Vegyületek és alkalmazási eljárásaik
HUE054437T2 (hu) Anti-CGRP készítmények és alkalmazásuk
HUE046559T2 (hu) Policiklusos karbamoilpiridon vegyületek és gyógyszerészeti alkalmazásuk
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
HUE052835T2 (hu) Pirrolobenzodiazepinek és konjugátumaik
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
HUE056167T2 (hu) Roseburia flagellin és immun-moduláció
BR112015001211A2 (pt) novos ácidos 5-aminotetra-hidroquinolina-2-carboxílicos e sua utilização
HK1203493A1 (en) Substituted azabicycles and use thereof
HUE036778T2 (hu) Gombaellenes szerek és alkalmazásuk
BR112014000049A2 (pt) pirrolotriazinas substituídas com hidroximelilarilo e sua utilização
EP2818054A4 (en) METHOD FOR COOKING STEAM NOODLES AND DEVICE FOR COOKING STEAM NOODLES
SG11201500111VA (en) Peptides and uses thereof
HUE042531T2 (hu) ASIC1-ellenes antitestek és alkalmazásaik
HUE053068T2 (hu) Hosszú hatástartamú koagulációs faktorok és alkalmazásaik
SG11201501646PA (en) Peptides and their uses
HUE050438T2 (hu) Rekombináns fehérjék és terápiás alkalmazásuk
HUE053623T2 (hu) Vegyületek és azok felhasználása
HK1208053A1 (en) Antibody against transporter and use thereof
HK1214838A1 (zh) 肽及包含它們的疫苗